MacroGenics reported 30.74M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Amgen AMGN:US $ 4889M 478M
AstraZeneca AZN:LN 6.03B 627M
Biogen BIIB:US $ 2315.3M 99.4M
Bristol Myers Squibb BMY:US $ 9252M 682M
Daiichi Sankyo 4568:JP Y 178917M 37069M
Eli Lilly And LLY:US $ 4786.9M 140.1M
Epizyme EPZM:US $ 10.52M 5.74M
Gilead Sciences GILD:US $ 4827M 235M
Johnson & Johnson JNJ:US $ 16088M 343M
Karyopharm Therapeutics KPTI:US $ 21.46M 864K
MacroGenics MGNX:US 30.74M 13.87M
Merk MRK:US $ 8718M 93M
Pfizer PFE:US $ 11985M 1575M
Puma Biotechnology PBYI:US $ 41.42M 27.2M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M
Seattle Genetics SGEN:US $ 310.39M 42.54M